COVID-19 has impacted neurology practices across the globe, driving neurologists to quickly adapt to new and unique challenges. In this virtual industry therapeutic update, discover 1) the key immunological considerations for vaccinating patients with neuroimmune disorders and 2) explore the learnings from the past year regarding neurology telemedicine.
What should neurologists know about the immune response to vaccines? Discover how mRNA and adenoviral vector COVID-19 vaccines work, key considerations surrounding neurology patient’s immune response to vaccines and what is involved in the generation of long-term immunity.
With the approval and distribution of mRNA and adenoviral vector vaccines for COVID-19, it is important to understand how these types of vaccines work and the implications of vaccinating people with MS. In the first section of the presentation, neurologist Barry Singer poses a series of questions to immunologist Amy Lovett-Racke on what neurologists should know about the immune response to vaccines. Together, they uncover the key considerations to take into account for vaccinating patients with MS.
What is the vaccination strategy if the virus continues to mutate? Learn why the emergence of SARS-CoV-2 variants may cause concern and how the vaccination strategy can be adapted to address this.
What immune markers indicate protection by COVID-19 vaccination? Learn about antibody responses upon primary and secondary exposure to antigen, and how these responses correlate with vaccine efficacy.
How do T cells respond to vaccination? Explore the evidence that T cells respond effectively to COVID-19 vaccines and delve deeper into their roles in generating a comprehensive immune response.
Explore what is known about the rare incidence of neurological complications, such as Guillain-Barré Syndrome and transverse myelitis, in response to infection and/or vaccination.
As neurologists have rapidly adjusted to treating patients virtually during the COVID-19 pandemic, what are the learnings to continue to move telemedicine forward? Discover the benefits and obstacles of teleneurology and explore what remote care may look like in the future.
In this second part of the presentation, Dr Barry Singer and Dr Carlo Tornatore review their experiences practising neurology telemedicine. Together, they explore the advantages and challenges of virtual neurology visits and identify the opportunities to optimise remote patient care for effective use post-COVID-19.
What has been learned from using a teleneurology platform over the past year? Dr Singer and Dr Tornatore discuss their own experiences with the increased use of telemedicine and the advantages it offers patients, caregivers, and neurologists.
Are there new tools to help neurologists adapt to remote care? Explore the patient-reported outcomes and numerous other tools currently available and/or being validated to assess patients remotely.
Dr Barry Singer is Director and Founder of The MS Center for Innovations in Care at Missouri Baptist Medical Center in St. Louis. He is an Associate Professor of Clinical Neurology at Washington University in St. Louis. Dr Singer has been an investigator in over 35 MS clinical trials focused on new therapeutics. In 2016, he was appointed to the board of directors of the Multiple Sclerosis Association of America. His award-winning MS patient education website www.mslivingwell.org started in 2007 and has been a valuable resource in greater than 190 countries.
Dr Amy Lovett-Racke is a Professor in the Department of Microbial Infection and Immunity and a member of the Infectious Diseases Institute at The Ohio State University Wexner Medical Center. She is also a Section Editor for the Journal of Immunology and serves as a committee member for the National Multiple Sclerosis Society’s Pathways to Cure MS. She has published extensively on the role of T cells, and their interactions with other cells of the immune and central nervous systems, in the onset and progression of multiple sclerosis.
Dr Carlo Tornatore serves as Professor and Chairman of the Department of Neurology at Georgetown University Medical Center. He is also Regional Chief of Neurology for MedStar Health, Chairman and Neurologist-in-Chief at Medstar Georgetown University Hospital, and Executive Director of the Multiple Sclerosis Patient Centered Specialty Practice MedStar Georgetown. Prof. Tornatore has published extensively in the areas of clinical and translational neuroimmunology and neurovirology and is actively involved in over 15 multiple sclerosis clinical trials.
Date of preparation: May 2021.